Evaxion to present three-year phase 2 EVX-01 melanoma vaccine efficacy data at ESMO 2026

Reuters2026/07/17 11:15

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evaxion flagged a potential data catalyst at ESMO 2026, outlining plans to present three-year phase 2 efficacy results for EVX-01 in advanced melanoma.
Update includes extension-trial readout on durability of immune response, including third-year EVX-01 monotherapy outcomes following earlier combination use with Keytruda.
Prior two-year follow-up showed 75% objective response rate, including four complete responses; 92% of responders remained in response with no relapses.
Presentation scheduled for Oct. 24, 2026, in Madrid; abstract focuses on sustained T-cell responses with durable disease control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170715OMX_____CNEWS_EN_GNW1001213232_en) on July 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evaxion to present three-year phase 2 EVX-01 melanoma vaccine efficacy data at ESMO 2026

You may also like

Crypto prices